MB
DSGN icon

MPM BioImpact’s Design Therapeutics DSGN Stock Holding History

MPM BioImpact’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-555,187
Closed -$4.18M – 43
2025
Q3 		$4.18M Hold
555,187
– – 0.68% 34
2025
Q2 		$1.87M Sell
555,187
-7,756
-1% -$29K 0.32% 41
2025
Q1 		$2.17M Buy
562,943
+3,396
+0.6% +$16.2K 0.37% 40
2024
Q4 		$3.45M Buy
+559,547
New +$3.24M 0.49% 42

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

MPM BioImpact's DSGN Position: Q4 2025 in Review

MPM BioImpact sold out of Design Therapeutics (DSGN) in Q4 2025, closing a stake of 555,187 shares — an estimated $4.18M sold.

MPM BioImpact first reported a position in DSGN in Q4 2024 and held it in 4 quarters. The position peaked at $4.18M in Q3 2025. 117 funds tracked by Wall St. Rank hold DSGN as of Q4 2025.

  • MPM BioImpact reported no remaining Design Therapeutics position as of Q4 2025 after selling out during the quarter.
  • MPM BioImpact sold 555,187 Design Therapeutics shares in Q4 2025, an estimated $4.18M.
  • MPM BioImpact first reported a position in Design Therapeutics in Q4 2024 and held it in 4 quarters.
  • MPM BioImpact's Design Therapeutics position peaked at $4.18M in Q3 2025.
  • 117 funds tracked by Wall St. Rank held Design Therapeutics as of Q4 2025.

Based on MPM BioImpact's 13F filing for Q4 2025, filed 17 Feb 2026.